<DOC>
	<DOCNO>NCT00934089</DOCNO>
	<brief_summary>This study characterize effect PF-04217329 , alone combination latanoprost , circadian intraocular pressure blood pressure glaucoma patient . Blood sample collect measure amount active metabolite PF-04217329 plasma follow dosing .</brief_summary>
	<brief_title>A Phase 2 Study Of The 24-Hour Intraocular Pressure Lowering And Systemic Exposure Of PF-04217329</brief_title>
	<detailed_description />
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<criteria>Diagnosis primary openangle glaucoma ocular hypertension one eye Intraocular Pressure ( IOP ) least 22 mmHg 30 mmHg either eye 8 AM discontinue previous glaucoma treatment Visual acuity correctable 20/100 good eye . Closed/barely open anterior chamber angle history acute angle closure either eye . Diagnosis clinically significant progressive retinal disease ( eg , diabetic retinopathy , macular degeneration ) either eye . Advanced glaucoma history severe central visual field loss either eye . History ocular surgery trauma either eye within 6 month screen visit . History ocular infection , ocular inflammation , laser surgery either eye within 3 month screen visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>